Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
-
Real-world effectiveness evidence among GSK data presented at ERS 2019
GlaxoSmithKline will for the first time share data on the effectiveness of mepolizumab in severe eosinophilic asthma patients
-
GSK receives positive CHMP opinion for intravenous Benlysta in children with lupus aged five years and above
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion
-
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
The US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old.
-
GSK to present data from its innovative oncology portfolio at ESMO Congress 2019
GSK announced that data from its growing oncology pipeline will be presented at the European Society for Medical Oncology Congress.
-
GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Belantamab mafodotin (GSK2857916) on track for regulatory submission by the end of 2019
-
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
ATLAS-2M study met its primary endpoint.
-
GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease
GSK announced, submission of JNDA for daprodustat, an oral HIF-PHI, for the treatment of renal anaemia due to CKD.
-
GSK announces leadership changes in the US
Jack Bailey, President US Pharmaceuticals has decided to step down from his role at the end of the year, succeeded by Maya Martinez-Davis.
-
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
-
Nucala receives EU approval for self-administration by patients with severe eosinophilic asthma
96% of patients in studies preferred self-administration at home over being treated in clinic
-
GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture
GSK today announced that it has completed its transaction with Pfizer to combine their consumer healthcare businesses into a Joint Venture.
-
Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements
Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe
-
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV
The marketing application is based on phase III ATLAS and FLAIR trials in which the regimen showed similar efficacy to daily, 3-drug one.
-
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
ViiV - GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir & lamivudine continues to demonstrate high efficacy rates
-
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
International AIDS Society Conference on HIV Science demonstrate non-inferior efficacy of Dovato▼ in virally suppressed adults with HIV
-
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
-
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
-
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from the BRIGHTE study of fostemsavir continue to show improvement in virologic suppression and immunologic response
-
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living with HIV